Charles Schwab Investment Management Inc. Has $15.04 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Charles Schwab Investment Management Inc. grew its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 1.5% during the 4th quarter, HoldingsChannel reports. The firm owned 540,692 shares of the company’s stock after acquiring an additional 8,096 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Akero Therapeutics were worth $15,042,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Victory Capital Management Inc. acquired a new stake in Akero Therapeutics during the third quarter worth about $211,000. Intech Investment Management LLC acquired a new stake in Akero Therapeutics during the third quarter worth about $491,000. Algert Global LLC grew its position in Akero Therapeutics by 8.3% during the third quarter. Algert Global LLC now owns 68,052 shares of the company’s stock worth $1,952,000 after buying an additional 5,191 shares in the last quarter. Summit Financial Wealth Advisors LLC acquired a new stake in Akero Therapeutics during the third quarter worth about $205,000. Finally, FMR LLC grew its position in Akero Therapeutics by 732.1% during the third quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after buying an additional 26,691 shares in the last quarter.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $44.66 on Friday. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The firm has a 50 day moving average of $43.53 and a 200-day moving average of $34.28. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $3.56 billion, a P/E ratio of -11.91 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). As a group, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Insider Activity

In related news, CFO William Richard White sold 676 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $30,338.88. Following the completion of the transaction, the chief financial officer now owns 61,959 shares in the company, valued at $2,780,719.92. The trade was a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Patrick Lamy sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the transaction, the vice president now owns 33,492 shares of the company’s stock, valued at $1,910,048.76. This trade represents a 12.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 252,135 shares of company stock worth $12,345,079. Insiders own 7.94% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on AKRO. HC Wainwright lifted their target price on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, March 3rd. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $76.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.